Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

Summary

The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from various specimen formats including malignant fluids such as pleural effusions and ascites, core needle biopsies, fine needle aspirates, or resections.

Conditions

• Pleural Effusion, Malignant
• Ascites, Malignant
• Carcinoma
• Carcinoma, Hepatocellular
• Carcinoma, Renal Cell
• Carcinoma, Renal
• Carcinoma, Small Cell
• Carcinoma, Non-Small-Cell Lung
• Carcinoma, Pancreatic Ductal
• Carcinoma, Neuroendocrine
• Carcinoma, Thymic
• Carcinoma, Pancreatic
• Carcinoma Breast
• Carcinoma, Ovarian
• Carcinoma Bladder
• Carcinoma of Unknown Primary
• Carcinoma of the Head and Neck
• Carcinoma of the Oropharynx
• Carcinoma of the Larynx
• Carcinoma of the Bladder
• Carcinoma of Esophagus
• Carcinoma of the Nasopharynx
• Carcinoma of the Penis
• Carcinoma of the Cervix
• Carcinoma of the Anus
• Carcinoma of the Vulva
• Carcinoma of the Appendix
• Carcinoma of the Oral Cavity
• Cholangiocarcinoma
• Melanoma
• Mesothelioma
• Pancreatic Cancer

Sponsors & Collaborators

• xCures

  collaborator INDUSTRY

• Travera Inc

  lead INDUSTRY

Principal Investigators

• Mark Stevens, Phd · Travera Inc

• Rob Kimmerling, Phd · Travera Inc

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2022-07-15

Primary Completion

2026-03-23

Completion

2026-03-23

Countries

• United States

Study Locations